Royalty Pharma's Offer for Elan (ELN) Viewed as Compelling

Deutsche Bank today maintained a Hold rating on Elan (NYSE: ELN). This morning investors learned that Royalty Pharma increased its offer to $13 per share plus CVR potentially worth $2.50. Deutsche Bank's Richard Parke said the offer was "compelling."

Commenting, Parkes said, "Royalty Pharma's offer is now well above our $12.1/share NPV and also factors in reward for shareholders if upside to Tysabri consensus forecasts is achieved. As a result we believe it offers a compelling alternative for Elan shareholders and significantly increases the probability that Royalty Pharma’s tender will be successful."

For an analyst ratings summary and ratings history on Elan Corp click here. For more ratings news on Elan Corp click here.

Shares of Elan Corp closed at $12.68 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• New Street Research Upgrades Micron Technology (MU) to Buy
• SoundThinking (SSTI) PT Lowered to $8 at Cantor Fitzgerald